In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and …
NE Scangarella-Oman, KA Ingraham… - Antimicrobial Agents …, 2020 - Am Soc Microbiol
ABSTRACT A phase 2 study of gepotidacin demonstrated the safety and efficacy of 3
gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h …
gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h …
[HTML][HTML] In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial …
NE Scangarella-Oman, KA Ingraham… - Antimicrobial Agents …, 2020 - ncbi.nlm.nih.gov
ABSTRACT A phase 2 study of gepotidacin demonstrated the safety and efficacy of 3
gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h …
gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h …
In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and …
NE Scangarella-Oman, KA Ingraham… - Antimicrobial …, 2020 - pubmed.ncbi.nlm.nih.gov
A phase 2 study of gepotidacin demonstrated the safety and efficacy of 3 gepotidacin doses
(750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h [q8h]) in hospitalized …
(750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h [q8h]) in hospitalized …
In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and …
NE Scangarella-Oman, KA Ingraham… - Antimicrobial Agents …, 2020 - europepmc.org
ABSTRACT A phase 2 study of gepotidacin demonstrated the safety and efficacy of 3
gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h …
gepotidacin doses (750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h …
In vitro activity and microbiological efficacy of gepotidacin from a phase 2, randomized, multicenter, dose-ranging study in patients with acute bacterial skin and skin …
NE Scangarella-Oman, KA Ingraham, CA Tiffany… - 2020 - cabidigitallibrary.org
A phase 2 study of gepotidacin demonstrated the safety and efficacy of 3 gepotidacin doses
(750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h [q8h]) in hospitalized …
(750 mg every 12 h [q12h], 1,000 mg q12h, and 1,000 mg every 8 h [q8h]) in hospitalized …